Internal Funding Opportunity

Commercial Proof of Principle Grant Competition

Take your invention to the next level.

IP&C’s annual Commercial Proof of Principle (PoP) grant competition helps advance promising SickKids discoveries or inventions towards commercial products, with a view to attract new investment, enable partnerships and create new life science-based companies. Recipients receive project funding and support services to position them for the next step on their path towards commercialization: partnership, licensing or start-up formation.

To learn more about the PoP grant competition, contact the IP&C office at ask.ipc@sickkids.ca.

“PoP Funding allowed our team to conduct a clinical study for our orthopaedic medical device, with results demonstrating the device’s efficacy and indicating significant patient demand, With licensing on the horizon, this work has inspired us to continue innovating to bring novel ideas to the orthopaedic device market”

Dr. Maryse Bouchard, Paediatric Orthopaedic Surgeon, SickKids Project Investigator
$0
Total funds awarded through PoP to support innovation at SickKids
YearAwardPrincipal InvestigatorProject TitleClassification
2016$100,000Dr. Charles DeberDevelopment of novel antimicrobial peptides against bacterial biofilmsTherapeutic
2017$100,000Dr. Brian KavanaghNegative abdominal pressure for injured lungsMedical Device
2017$100,000Dr. Roman MelnykAdvancing the development of a potent RAS-targeted therapeuticTherapeutic
2018$56,000Dr. Adrian JamesSteerable Endoscopic Ear Surgery InstrumentMedical Device
2018$99,680Dr. Jason MaynesMachine Learning Algorithms for Toxicity and Cardiac Health (MATCH)Therapeutic
2018$148,199Dr. Jean-Philippe JulienIn vivo evaluation of the multabody platform for cancer immunotherapyTherapeutic
2019$100,000Dr. Robert HamiltonAutoantibodies to Actin, Keratin and Connexin as biomarkers/mechanisms for Brugada SyndromeDiagnostic
2019$99,800Dr. Cynthia HawkinsClinical development of liquid biopsy for cancer detection and monitoringDiagnostic
2019$100,000Dr. Lynne HowellBioactive surfaces to prevent microbial biofilmsMedical Device
2021$100,000Dr. Christine BearDeveloping a small molecule CFTR potentiator as a therapy for Chronic Obstructive Pulmonary Disease (COPD) or bronchitisTherapeutic
2021$100,000Dr. Maryse BouchardNovel Dynamic Foot Abduction Bar for Clubfoot Brace TreatmentMedical Device
2021$100,000Dr. Xi HuangTreating glioblastoma using an ion channel-targeting designer interference peptideTherapeutic
2022$100,000Dr. Roman MelnykAdvancing the development of gut-restricted bile acid derivatives to treat C. difficile diseaseTherapeutic
2022$100,000Dr. Steve PrescottAutomated pain behavior testing in miceMedical Device
2022$100,000Dr. Xi HuangIdentifying potassium channel modulators to target brain tumor-initiating cellsTherapeutic
2023$100,000Dr. Lu-Yang WangInnovating Positive Allosteric Modulators of Potassium Channels to Treat EpilepsyTherapeutic
2023$100,000 Dr. Xi HuangIdentifying Small Molecule Potassium Channel Inhibitors as Novel Cancer TherapeuticsTherapeutic
2023$100,000Dr. John ParkinsonSmart Capsule for Non-Invasive Targeted Sampling and Delivery in the GutMedical Device
2024$100,000Dr. Christine BearComparison of SickKids CFTR Potentiator to Ensifentrine in Ameliorating COPD in In-Vitro and In-Vivo ModelsTherapeutic
2024$100,000Dr. Jayne DanskaPlatform Conversion of Novel Antibody Biomarkers for Type 1 Diabetes and Patient Response to Preventative ImmunotherapyDiagnostic
2024$100,000Dr. Lynne HowellIn Silico Designed Glycoside Hydrolases for Treatment of Biofilm InfectionsTherapeutic
TOTAL$2,103,679